Spots Global Cancer Trial Database for Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
Official Title: An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
Study ID: NCT00582985
Interventions
Study Description
Brief Summary: This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
Detailed Description: In addition to safety, this study will also evaluate pharmacokinetics, tumor response and anti-TRC105 antibody formation.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Scottsdale, Arizona, United States
, Santa Monica, California, United States
, Buffalo, New York, United States
, Durham, North Carolina, United States
Contact Details
Name: Bryan R Leigh, MD
Affiliation: Tracon Pharmaceuticals Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
